Leukemia Research
Volume 33, Issue 2 , Pages 244-249 , February 2009

Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation

  • Z.Y. Lim

      Affiliations

    • Department of Haematological Medicine, Kings College Hospital, London, UK
    • On behalf of the British Society of Bone Marrow Transplantation.
    • ,
  • G. Cook

      Affiliations

    • Department of Haematology, St. James University Hospital, Leeds, UK
    • On behalf of the British Society of Bone Marrow Transplantation.
    • ,
  • P.R. Johnson

      Affiliations

    • Department of Haematology, Western General Hospital, Edinburgh, UK
    • On behalf of the British Society of Bone Marrow Transplantation.
    • ,
  • Anne Parker

      Affiliations

    • Department of Haematology, Glasgow Royal Infirmary, UK
    • On behalf of the British Society of Bone Marrow Transplantation.
    • ,
  • M. Zuckerman

      Affiliations

    • Department of Virology, Kings College Hospital, London, UK
    • On behalf of the British Society of Bone Marrow Transplantation.
    • ,
  • D. Marks

      Affiliations

    • Department of Haematology, Bristol Royal Infirmary, UK
    • On behalf of the British Society of Bone Marrow Transplantation.
    • ,
  • H. Wiltshire

      Affiliations

    • Roche Products Ltd., Welwyn Garden City, UK
    • On behalf of the British Society of Bone Marrow Transplantation.
    • ,
  • G.J. Mufti

      Affiliations

    • Department of Haematological Medicine, Kings College Hospital, London, UK
    • On behalf of the British Society of Bone Marrow Transplantation.
    • ,
  • A. Pagliuca

      Affiliations

    • Department of Haematological Medicine, Kings College Hospital, London, UK
    • On behalf of the British Society of Bone Marrow Transplantation.
    • Corresponding Author InformationCorresponding author. Tel.: +44 2032993709; fax: +44 2032993514.

Received 16 April 2008 ,Revised 7 July 2008 ,Accepted 17 July 2008.

References 

  1. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357–4363
  2. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815–2820
  3. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601–1607
  4. Winston DJ, Baden LR, Gabriel DA, et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transpl. 2006;12:635–640
  5. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005–1011
  6. Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood. 2006;107:3002–3008
  7. Kearns AM, Turner AJ, Eltringham GJ, Freeman R. Rapid detection and quantification of CMV DNA in urine using LightCycler-based real-time PCR. J Clin Virol. 2002;24:131–134
  8. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther. 2002;72:142–150
  9. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005;79:1477–1483
  10. Shimoni A, Nagler A. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. Cancer Treat Res. 2002;110:113–136
  11. Gonzalez H, Vernant JP, Caumes E. Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy. Leukemia. 2005;19:478
  12. van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transpl. 2006;37:693–698
  13. Busca A, de Fabritiis P, Ghisetti V, et al. Oral valganciclovir as pre-emptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis. 2007;9:102–107
  14. Ayala E, Greene J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2006;37:851–856

PII: S0145-2126(08)00344-5

doi: 10.1016/j.leukres.2008.07.016

Leukemia Research
Volume 33, Issue 2 , Pages 244-249 , February 2009

Article Tools

* Image Usage & Resolution